Young scientists are the lifeblood of cancer research. Rich with new ideas and energy, these bright and talented minds are eager to solve important scientific questions. The Cancer Research Institute provides funding to ensure that the most promising postdoctoral scientists receive the critical financial support and continued career training needed to pursue their lifesaving work.
PROGRAM UPDATE: The Cancer Research Institute recognizes that getting to the next great breakthrough in cancer treatment will require continued investment in fundamental research and training. CRI therefore invites postdoctoral fellows working in both fundamental immunology and tumor immunology to apply for funding.
The CRI Irvington Postdoctoral Fellowship Program is CRI's longest-standing continuous program. Postdoctoral fellowships provide support to fund and train young immunologists and cancer immunologists at top universities and research centers around the world.
Fellows work and continue their training under the guidance of a world-renowned immunologist, who mentors the fellow and prepares him or her for a productive and successful career in cancer immunology.
Fellows receive up to $175,500 over three years to cover the cost of salary, insurance, and other research-related expenses, such as travel to conferences and meetings.
History & Accomplishments
Since this program’s inception, more than 1,350 young scientists have received postdoctoral fellowship awards from CRI. CRI Fellows have made groundbreaking discoveries that have laid the foundation for the field, and have gone on to lead major research programs and centers and to win some of the most prestigious awards in biomedical science, including the Nobel Prize.
More importantly, CRI Fellows have contributed to the discovery of numerous research discoveries that have since resulted in lifesaving treatments for cancer, infectious diseases, and autoimmune disorders.
View our funding directory to see the types of research CRI Irvington postdoctoral fellows are working on to change the face of cancer treatment.
See Application Guidelines